DC Lung Cancer Conference 2019


DC Lung Cancer Conference 2019 Banner

Add to Calendar DC Lung Cancer Conference 2019 11/16/2019 12:00:00 AM 11/16/2019 12:00:00 AM America/New_York For More Details: https://medstar.cloud-cme.com/lung Description: This one-day symposium will provide an update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection, to diagnosis to treatment. This symposium will emphasize current best practices for busy clinicians who care... Washington Marriott Wardman Park false MM/DD/YYYY


Date & Location
Saturday, November 16, 2019, 12:00 AM - 12:00 AM EST, Washington Marriott Wardman Park

Target Audience
Specialties - Internal Medicine, Medical Oncology, Nuclear Medicine, Oncology, Pathology, Pulmonology, Radiation Oncology, Radiology, Surgery

Overview
This one-day symposium will provide an update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection, to diagnosis to treatment. This symposium will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact didactic talks will be delivered by national thought leaders and well-respected faculty in each field. There will be updates on CT screening and smoking cessation, proper use of liquid biopsy, interpretation of molecular testing results and review of modern bronchoscopic interventions. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on proton beam radiation, minimally invasive surgery and immunotherapy as well as an introduction to oligometastatic cancer and its proper management. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over optimal management of metastatic, PD-L1 positive NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions and through a case-based format following each session with access to presentation materials for later review.

Objectives

At the conclusion of this activity, the learner will be able to:

Nurse Learning Objective:

1. Explain the benefit of CT screening for lung cancer

2. Discuss the current application of liquid biopsy (or ctDNA analysis)

3. Explain the role of multidisciplinary care for locally advanced non-small cell lung cancer

4. Identify nursing strategies for early detection of immune-mediated toxicities

5. Identify unique toxicities associated with targeted agents used in NSCLC

6. Recognize commune immune related adverse events and factors that increase patient risk

Pharmacist Learning Objective:

1. Discuss standard targeted agents in use for patients with driver-positive non-small cell lung cancer

2. Discuss the role of multidisciplinary care for locally advanced non-small cell lung cancer

3. Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer

4. Implement the pharmacologic management of immune-mediated adverse events based on current guidelines and evidence

Physician Learning Objective:


  1. Explain the benefit of CT screening for lung cancer
  2. Discuss the current application of liquid biopsy (ctDNA analysis)
  3. Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer
  4. Discuss management options for patients with oligometastatic non-small cell lung cancer
  5. Discuss standard targeted agents in use for patients with driver-positive non-small cell lung cancer
  6. Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer
  7. Debate the controversies of immunotherapy alone or chemo-immunotherapy for PD-L1 positive non-small cell lung cancer
  8. Discuss management of immune-mediated toxicities

Registration

Physician: $175
Resident or Fellow: $100
Physician Assistant: $100
Nurse Practitioner: $100
Nurse: $100
Pharmacist: $100
Allied Health: $100
Industry Professional: $250


Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

 

Pharmacy Credit

This curriculum has been approved for 6.5 contact hours by MedStar Health. MedStar Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The Universal Activity Number for this program is JA4008151-0000-19-026-L01- P. This learning activity is knowledge-based.


Credits
AMA PRA Category 1 Credits™ Physician (6.25 hours), IPCE (6.25 hours), Non-Physician Member of the Healthcare Team (6.25 hours), Nurse - ANCC (6.25 hours), Pharmacist - ACPE (6.25 hours)